In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CAT buys Drug Royalty Corp. for $78mm; agreement terminated

Executive Summary

Cambridge Antibody Technology (human monoclonal antibodies) has agreed to buy Drug Royalty Corp. (acquires royalty interest in drugs) for stock. CAT will pay Drug Royalty shareholders $1.86 ($Cdn3) per share (a 6% premium to the market average) for all outstanding DRC shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies